Next Article in Journal
Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer’s Disease
Next Article in Special Issue
Silibinin Anticancer Effects Through the Modulation of the Tumor Immune Microenvironment in Triple-Negative Breast Cancer
Previous Article in Journal
Genome-Wide Identification, Phylogeny, and Abiotic Stress Response Analysis of OSCA Family Genes in the Alpine Medicinal Herb Notopterygium franchetii
Previous Article in Special Issue
Anticancer Activity and Mechanism of Action of Couroupita guianensis Bark Decoction in Gastric Adenocarcinoma Cancer Cell Line
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 11
10.3390/ijms26115045
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

The Combination of CD300c Antibody with PD-1 Blockade Suppresses Tumor Growth and Metastasis by Remodeling the Tumor Microenvironment in Triple-Negative Breast Cancer

Int. J. Mol. Sci. 2025, 26(11), 5045; https://doi.org/10.3390/ijms26115045
by Soyoung Kim 1,†, Ik-Hwan Han 1,†, Suin Lee 2, DaeHwan Park 1, Hyunju Lee 1, Jongyeob Kim 2, Joon Kim 2, Jae-Won Jeon 2,* and Hyunsu Bae 1,*
Reviewer 1:
Ming-Shen Dai
Reviewer 2:
Sekena Abdel-Aziem
Int. J. Mol. Sci. 2025, 26(11), 5045; https://doi.org/10.3390/ijms26115045
Submission received: 20 April 2025 / Revised: 20 May 2025 / Accepted: 21 May 2025 / Published: 23 May 2025
(This article belongs to the Special Issue Bioactive Compounds and Their Anticancer Effects)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

This study proposed that combining tumor associated macrophage (TAM) reprogramming with immune checkpoint blockade is a potential treatment strategy for triple-negative breast cancer (TNBC) through modulation of M1/M2 ratio, activating CD8-T cell, and NK cells. I have 2 questions to the study.

  1. Did you analyze the tumor section with IHC or multiplex IHC staining of the macrophage/CD8+T cell/NK distribution within tumors?
  2. In previous paper (Immunobiology. 2024 Jan;229(1):152780), did you have similar finding of increased PD-L1 expression after CD300c treatment?

Author Response

Thank you for your valuable comments.
We have revised the manuscript accordingly.
Please see the attached revised manuscript for details.

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

Dear authors:

This well-designed study demonstrates promising efficacy of combined CL7 (CD300c antibody) and anti-PD-1 therapy in TNBC by remodeling the tumor microenvironment through increased M1 macrophages and activated CD8+ T/NK cells. While the methodology is robust and results clearly presented, the manuscript would benefit from: (1) stronger mechanistic rationale in the introduction for targeting CD300c specifically; (2) more detailed justification of experimental parameters (doses, timing, sample sizes); and (3) brief discussion of limitations (e.g., translational challenges). These revisions would enhance the paper's impact without requiring additional experiments. The study's novel approach and compelling data make it suitable for publication after addressing these points.

Author Response

Thank you for your valuable comments.
We have revised the manuscript accordingly.
Please see the attached revised manuscript for details.

Author Response File: Author Response.pdf

Back to TopTop